Sandoz Declares New Global ‘Act4biosimilars’ Program to Enhance Patient Access

A global leader in generic and biosimilar medicines, Sandoz, today declared the release of a new global initiative called ‘Act4Biosimilars’ to address health inequity and inequality worldwide.

For the prevention of many disabling and life-threatening diseases such as psoriasis, arthritis, cancer, and diabetes, Biosimilars are used in the treatment.

The main aim of Act4Biosimilars is to enhance patient access to advanced medicines by enabling greater approvability, accessibility, acceptability, and affordability–the 4 A’s–of biosimilars.

The program is sponsored by healthcare professionals, multidisciplinary Steering Committee of patient advocacy leaders, biosimilar experts, and industry leaders from around the globe. The mission of this initiative is to expand global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.

Read More News: Click Here